Aulendorf (DE)
{name}
{subtitle}
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
city
~16 mi. (Ravensburg, Germany, +144 more cities)
facility
GSK Investigational Site
condition
Endometrial Carcinoma
drug
carboplatin, +3 more drugs
drug type
chemotherapy, +2 more types
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
city
~16 mi. (Ravensburg, Germany, +170 more cities)
facility
Novartis Investigative Site
biomarker
ER Negative, +4 more biomarkers
condition
Breast Carcinoma
drug
alpelisib, +1 more drug
drug type
chemotherapy, +1 more type
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)
city
~16 mi. (Ravensburg, Germany, +76 more cities)
facility
Onkologie Ravensburg ( Site 1104)
condition
Non-Small Cell Lung Carcinoma
drug
docetaxel, +1 more drug
drug type
chemotherapy, +1 more type
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
city
~47 mi. (Ulm, Germany, +150 more cities)
facility
Universitaetsklinikum Ulm ( Site 0402)
condition
Head and Neck Squamous Cell Carcinoma
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +2 more types
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~47 mi. (Ulm, Germany, +127 more cities)
facility
Universitaetsklinikum Ulm ( Site 2102)
condition
Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
city
~47 mi. (Ulm, Germany, +105 more cities)
facility
Universitaetsklinikum Ulm ( Site 0500)
condition
Colorectal Adenocarcinoma
drug
bevacizumab, +1 more drug
drug type
targeted therapy
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
city
~47 mi. (Ulm, Germany, +141 more cities)
facility
GSK Investigational Site
condition
Multiple Myeloma
drug
belantamab mafodotin
drug type
chemotherapy, +1 more type
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
city
~47 mi. (Ulm, Germany, +160 more cities)
facility
Ulm University Hospital Klinik für Frauenheilkunde und Geburtshilfe
biomarker
FOLR1 Expression
condition
Fallopian Tube Carcinoma, +2 more conditions
drug
mirvetuximab soravtansine
drug type
chemotherapy, +1 more type
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
city
~47 mi. (Ulm, Germany)
facility
University Hospital Ulm -Department of Gynecology
biomarker
ER Positive, +2 more biomarkers
condition
Breast Carcinoma
drug
eribulin, +2 more drugs
drug type
chemotherapy, +2 more types